Fibrinogen

75

Specific Proteins

Fibrinogen

Fresh citrate plasma

R1 (Buffer): 1 x 25.0 mL;
R2 (Antiserum): 1 x 5.0 mL,
Ready to use

Instructions for Use  |  Safety Data Sheet

For professional in vitro diagnostic use only.

Minimising blood loss is accomplished by three events. One is a clumping of platelets in the blood at the site of injury. Another is a vasoconstriction of the injured vessel to reduce the flow through the break. The third event is aggregation of a protein, fibrin, into a clot – a stable three-dimensional lattice-that is strong enough to seal the damaged vessel while repairs are being made. Clotting occurs because a soluble blood plasma protein, fibrinogen, is partially hydrolysed to form fibrin. Elevated levels of fibrinogen in plasma are to be expected in inflammatory processes, after major trauma or surgery and also occur with metastasing tumours. Decreased levels of fibrinogen can occur in consumption coagulopathies, e.g. disseminated intravascular coagulation (DIC), primary hyperfibrinolysis, hepatic insufficiency and genetic deficiency. Epidemiological studies have shown that elevated plasma levels of fibrinogen are associated with an increased risk of arteriosclerosis.

Measurement of antigen-antibody reaction by the end-point method.

The reagents are stable until expiry date when kept at 2-8°C. Stability in the instrument is at least 4 weeks if contamination is avoided. Do not freeze.

Saline (9 g/L NaCl)
Fibrinogen Standard, 0.5 mL (R1300002201)
Fibrinogen Control, 1 mL (R1400001701)